Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Comprehensive Loss (Unaudited)

v3.21.1
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]    
Product Revenue
Product Cost of Sales
Gross Income
Research and Development Expenses (19,365) 2,483,057
Administrative Expenses 1,508,336 1,055,148
Sales and Marketing Expenses 6,250
Loss from Operations (1,488,971) (3,544,455)
Other (Income) Expenses    
(Gain)/Loss on Investments (12,649) 36,714
Loss on Fair Market Value of Equity Investments 14,402
Interest and Dividend Income (43,453) (46,703)
Total Other Income (41,700) (9,989)
Loss from Continuing Operations Before Income Tax (1,447,271) (3,534,466)
Income Tax Benefit
Loss from Continuing Operations (1,447,271) (3,534,466)
Loss from Discontinued Operations Before Income Tax (35,392) (4,070)
Income Tax
Loss from Discontinued Operations (35,392) (4,070)
Net Loss (1,482,663) (3,538,536)
Other Comprehensive Income (Loss)    
Net Unrealized Loss on Marketable Securities (240,937)
Total Other Comprehensive Income (Loss) (240,937)
Comprehensive Loss $ (1,482,663) $ (3,779,473)
Basic and Diluted loss per common share from continuing operations $ (0.17) $ (3.18)
Basic and Diluted loss per common share from discontinued operations (0.00) (0.00)
Basic and Diluted loss per common share $ (0.17) $ (3.18)
Weighted average basic common shares outstanding 8,544,298 1,113,737